Viridian Therapeutics, Inc./DE (VRDN) Return on equity 2017–2025
Viridian Therapeutics, Inc./DE (VRDN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-47.4%FY2025 · since FY2017: -68.8% → -47.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -47.4% | -7.2 pp |
| FY2024 | -40.2% | +13.6 pp |
| FY2023 | -53.8% | -20.9 pp |
| FY2022 | -32.9% | +9.4 pp |
| FY2021 | -42.3% | +49.9 pp |
| FY2020 | -92.2% | +173.6 pp |
| FY2019 | -265.8% | -202.1 pp |
| FY2018 | -63.7% | +5.2 pp |
| FY2017 | -68.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More VRDN financial trends
VRDN RevenueVRDN Net incomeVRDN Net marginVRDN Gross profitVRDN Gross marginVRDN Operating incomeVRDN Operating marginVRDN Operating cash flowVRDN Free cash flowVRDN Capital expendituresVRDN Stock buybacksVRDN Dividends paidVRDN Total assetsVRDN Total liabilitiesVRDN Shareholders’ equityVRDN overview →